Form 4: Bristol-Myers Squibb Executive's Planned RSU Conversion

A Bristol-Myers Squibb executive reported a future transaction under a 10b5-1 plan involving RSU conversion and tax-related share sale.

Summary

• Wendy Short Bartie, EVP, Corporate Affairs at Bristol-Myers Squibb, reported planned transactions under a Rule 10b5-1 plan, scheduled for September 1, 2025.
• The transactions include the acquisition of 1,235 shares of common stock, $0.10 par value, through the conversion of Restricted Stock Units (RSUs).
• Concurrently, 632 shares were planned to be disposed of at a price of $47.18 per share to satisfy tax withholding obligations related to the vesting of these awards.
• Following these planned transactions, the executive will directly own 5,669 shares of Bristol-Myers Squibb common stock.
• The Restricted Stock Units vest in four equal installments, with the first installment having begun on September 1, 2023.
• An additional 1,236 Restricted Stock Units remain beneficially owned by the executive after the reported conversion.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The conversion of RSUs is a positive event for the executive, indicating compensation realization. The sale for tax purposes is standard practice and not inherently negative, but it does reduce direct ownership. The transaction being under a 10b5-1 plan adds a layer of transparency and compliance.

Positives

• The transaction is part of a pre-arranged Rule 10b5-1 plan, indicating a structured and compliant approach to executive compensation and share management.
• The conversion of Restricted Stock Units represents the realization of long-term incentive compensation for the executive, aligning interests with shareholders.
• The executive will continue to hold a significant number of shares (5,669 common shares and 1,236 RSUs) after the planned transactions.

Negatives

• A portion of the acquired shares (632 shares) is planned to be sold to cover tax liabilities, which will reduce the executive's direct ownership post-conversion.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is an insider transaction report.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Minor impact. The executive's ownership slightly decreased due to tax withholding, but the overall RSU conversion indicates continued executive alignment with shareholder interests.
• Employees: No direct impact on the broader employee base.

Next Steps

• Ongoing vesting of remaining Restricted Stock Units in accordance with the established four-equal-installment schedule, which began on September 1, 2023.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Executive Compensation, Stock Sale, Tax Withholding, 10b5-1 Plan